newsfilter
← Latest News
ACCESS Newswire·

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that